Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Carrick Therapeutics logo — Transformative Cancer Medicines

Carrick Therapeutics

Transformative Cancer Medicines

Founded 2015 Ireland Ireland 16 employees Series C Total: $155.00M Biotechnology, Health Care +2

General Information

Company Name Carrick Therapeutics
Founded Year 2015
Location Ireland Ireland
Employees 16
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Carrick Therapeutics. To contact Carrick Therapeutics, visit carricktherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Carrick Therapeutics compare?

A PDF of Carrick Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Carrick Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Carrick Therapeutics

Carrick Therapeutics is a biotechnology startup based in Ireland, founded in 2015. The company is dedicated to developing innovative treatments for aggressive forms of cancer with the aim of transforming cancer treatment. Its mission revolves around revolutionizing cancer treatment by creating a diverse range of therapies that specifically target the most aggressive forms of cancer through multiple mechanisms. Carrick Therapeutics utilizes state-of-the-art technologies and a deep understanding of the underlying causes of cancer and resistance to develop first-in-class treatments tailored to specific patient populations. The company collaborates with leading research institutions and hospitals worldwide and is committed to advancing its revolutionary cancer therapies from the laboratory to the clinic. At the end of 2022, Carrick Therapeutics secured a significant $60.00M Series C investment from a consortium of prestigious investors, including Arch Venture Partners, GV, Lightstone Ventures, Cambridge Innovation Capital, Evotec, Revelation Partners, Rosetta Capital, and Pfizer. This indicates strong support and confidence from established players in the industry. With its innovative approach and impressive financial backing, Carrick Therapeutics is well-positioned to make a substantial impact on cancer treatment, addressing the highest unmet medical needs of patients.

Business keywords: Cancer treatment, Innovative therapies, Aggressive cancer, Precision medicine, Clinical research, Targeted therapy, Medical technology, Research collaboration, Unmet medical needs

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $60.00M 8
Arch Venture Partners GV Lightstone Ventures
Arch Venture Partners, GV +6
01 Dec 2022
Series A $95.00M 2
Cambridge Innovation Capital Woodford Patient Capital Trust
Cambridge Innovation Capital, Woodford Patient Capital Trust
03 Oct 2016

Carrick Therapeutics Alternatives & Competitors

View All Alternatives
Carrick Therapeutics vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
Carrick Therapeutics vs
Kintara Therapeutics, Inc. NASDAQ: KTRA
Kintara Therapeutics, Inc. NASDAQ: KTRA United States

Seeking New Horizons for Cancer Patients

Grant
8 employees
Biotechnology, Health Care
Carrick Therapeutics vs
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. United States

Delivering a cancer-free future

Post-IPO Equity
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Carrick Therapeutics

Transformative Cancer Medicines
Carrick Therapeutics was founded in 2015.
Carrick Therapeutics is headquartered in Ireland.
Carrick Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on Cancer treatment, Innovative therapies, Aggressive cancer and Precision medicine.
Carrick Therapeutics has approximately 16 employees.
Carrick Therapeutics has completed 2 funding rounds, raising a total of $155.00M. The latest funding stage is Series C.
Top alternatives and competitors to Carrick Therapeutics include Prescient Therapeutics, Kintara Therapeutics, Inc. NASDAQ: KTRA, TransCode Therapeutics, Inc., Probmet Therapeutics, Orca Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Carrick Therapeutics and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Carrick Therapeutics, https://bouncewatch.com/company/carrick-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout